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Dextran sulfate modulates MAP kinase signaling
and reduces endothelial injury in a rat aortic
clamping model
Yara Banz, MD, PhD,a,b Thusitha Gajanayake, PhD,a Katja Matozan,a Zhihong Yang, PhD,c and
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Objective: Mitogen-activated protein kinases (MAPKs), including JNK, p38, and ERK1/2, noticeably inﬂuence isch-
emia/reperfusion injury (IRI). The complement inhibitor dextran sulfate (DXS) associates with damaged endothelium
denudated of its heparan sulfate proteoglycan (HSPG) layer. Other glycosaminoglycan analogs are known to inﬂuence
MAPK signaling. Hypothetically therefore, targeted intravascular cytoprotection by DXS may function in part through
inﬂuencing MAPK activation to reduce IRI-induced damage of the vasculature.
Methods: IRI of the infrarenal aorta of male Wistar rats was induced by 90 minutes clamping followed by 120 minutes
reperfusion. DXS (5 mg/mL) or physiologic saline (NaCl controls) was infused locally into the ischemic aortic segment
immediately prior to reperfusion. Ninety minutes ischemia-only and heparinase infusion (maximal damage) experiments,
as well as native rat aorta, served as controls. Aortas were excised following termination of the experiments for further
analysis.
Results: DXS signiﬁcantly inhibited IRI-induced JNK and ERK1/2 activation (P  .043; P .005) without inﬂuencing
the p38 pathway (P .110). Reduced aortic injury, with signiﬁcant inhibition of apoptosis (P  .032 for DXS vs NaCl),
correlated with decreased nuclear factor B translocation within the aortic wall. DXS treatment clearly reduced C1q,
C4b/c, C3b/c, and C9 complement deposition, whilst preserving endothelial cell integrity and reducing reperfusion-
induced HSPG shedding. Protection was associated with binding of ﬂuorescein labeled DXS to ischemically damaged
tissue.
Conclusions: Local application of DXS into ischemic vasculature immediately prior to reperfusion reduces complement
deposition and preserves endothelial integrity, partially through modulating activation of MAPKs and may offer a new
approach to tackle IRI in vascular surgical procedures. ( J Vasc Surg 2009;50:161-70.)
Clinical Relevance: The purpose of the present study was to determine the role of dextran sulfate (DXS), a glycosami-
noglycan analog and complement inhibitor, in modulating intracellular MAPK signaling pathways, reducing comple-
ment activation and ultimately attenuating ischemia/reperfusion injury (IRI) in a rat aortic-clamping model, in part a
surrogate model to study the microvasculature. The study shows a role for DXS in ameliorating endothelial injury by
reducing IRI-mediated damage and intravascular, local inﬂammation in the affected aortic segment. DXS may be
envisaged as an endothelial protectant in vascular injury, such as occurs during vascular surgical procedures.
Mitogen-activated protein kinases (MAPK), compris-
ing extracellular signal-regulated kinases (ERK1/2), c-Jun
NH2-terminal kinase (JNK), and p38-MAPK, are a multi-
gene family of serine/threonine protein kinases, which
respond to a wide variety of stimuli, including environmen-
tal stresses and growth factors.1
Several studies have demonstrated a role for the MAPK
family in ischemia/reperfusion injury (IRI). Activation of
stress-induced JNK as well as p38 MAPK occurs upon
ischemia and ensuing reperfusion,2 signiﬁcantly contribut-
ing to target organ injury, and inhibition of the JNK and
p38 MAPK pathways protects the ischemic and reperfused
heart.3 Conversely, the ERK1/2 pathway has been shown
to be protective.4 However, the situation is complex; a
dynamic balance of the activities of these kinases may prove
critical in deciding the outcome post-IRI. Endothelial cell
(EC) activation is central to IRI. Disruption of the surface-
protective endothelial glycocalyx layer,5 upregulation of
endothelial adhesion molecules,6 as well as loss of antico-
agulant properties7 promote a proinﬂammatory and proco-
agulant environment. Furthermore, activation and local
upregulation of complement proteins8 plays a pivotal role
in mediating tissue damage.
Complement-mediated induction of MAPK pathways,
including ERK1/2 and JNK, has been described in mito-
genic signaling in a variety of cells9 as well as chemotaxis in
neutrophils through C5a receptor signaling.10
Low molecular weight dextran sulfate (DXS, MW
5000), a glycosaminoglycan analog, is a well-typiﬁed inhib-
itor of complement and coagulation pathways11,12 and
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associates with EC denudated of their glycocalyx heparan
sulfate proteoglycans (HSPG).13 We have observed that
DXS not only localizes to the cell surface but is also found
intracellularly and inhibits phosphorylation of IB- and
activation of nuclear factor B.14 DXS may therefore inﬂu-
ence intracellular signaling pathways. We postulated that,
similar to glycosaminoglycans, DXS might also modulate
MAPK signaling. The aim of this study therefore was to
investigate aortic ischemic endothelial damage in a rat model
and whether association of DXS with damaged endothelium
and its known cytoprotective and complement-inhibitory
effects correlate with modulation of the MAPK pathways.
This model may be of particular interest in vascular surgery,
to study larger vessels, including the aorta, as well as surro-
gate for the (micro-) vasculature of the target organ(s),
which may be subjected to longer periods of ischemic
assault during, amongst others, complex surgical (revascu-
larization) procedures.
MATERIALS AND METHODS
Materials. Low molecular weight DXS (sodium salt,
MW 5000) was purchased from Sigma Chemical Company
(St Louis, Mo). Fluorescein-labeled DXS (DXS-Fluo) was
produced using ﬂuorescein cadaverine (Molecular Probes
Europe, Leiden, The Netherlands) as described earlier.13 It
was veriﬁed that DXS-Fluo essentially had identical bio-
chemical properties as the unlabeled substance.
Experimental procedure. The experimental protocol
was approved by the veterinary ofﬁce of the Canton of
Bern, Switzerland. Care and use of animals in the present
study was in compliance with national (Federal Law no.
455 on the protection of animals, 2005) as well as interna-
tional guidelines. (Guide for the Care and Use of Labora-
tory Animals, NIH Publication No. 85-23, revised 1996).
A total of 80 male Wistar rats (270  65 g) were
anesthetized by isoﬂurane/oxygen, through a semi-closed
circuit inhalation system; spontaneous breathing was mon-
itored and maintained throughout. The animals were
placed on a heating pad and body temperature controlled
to 37  1°C. Prewarmed physiologic saline was adminis-
tered intraperitoneally during the experiment, adapted to
body weight and eventual blood loss from the aortic injec-
tion site (2.5 mg/kg/h  approximated volume of blood
loss).
A summary of the experimental design, detailed below,
is given in Fig 1.
Following a midline abdominal incision, the infrarenal
aorta was mobilized as described by Neil et al.15 Although
in a majority of the animals the clamped segment did not
include lumbar arteries, where present, they were cauter-
ized to ensure complete isolation of the aortic segment.
After preparation, the aorta was clamped just distally of the
renal arteries and carefully ﬂushed with 1 mL of physiologic
saline to remove any traces of blood. A second clamp was
placed approximately 1 cm distally of the ﬁrst clamp, prox-
imally of the aortic bifurcation. After 90 minutes of isch-
emia, 200 L physiologic saline (NaCl, controls, n  20)
or 200 L of 5 mg/mL of DXS in NaCl (n  20) were
infused into the lumen of the ischemic aortic segment. Five
minutes later, ﬁrst the distal, then the proximal clamp were
released and the aortic segment was reperfused for 120
minutes. The dose of DXS (4 mg/kg body weight) was
chosen from experience with previous experiments where
in vivo dosages between 8 mg/kg up to 25 mg/kg were
well tolerated, nontoxic and effectively without unwanted
side effects.16,17
Fifteen ischemia-only control experiments were per-
formed in which the animals were sacriﬁced and the aortas
excised after 90 minutes of clamping without reperfusion.
In a further 15 experiments, DXS-Fluo was used in-
stead of the normal, unlabeled substances. These experi-
ments were done in order to evaluate the binding of DXS to
the endothelium and aortic wall. At the end of the experi-
ments, the rats were sacriﬁced and the aortas were harvested
for further evaluation.
Heparinase III treatment. With the hypothesis that
endothelial HSPG release may play an important role in IRI
and that this release prompts DXS binding, rats were sub-
jected to aortic clamping for 10 minutes, during which 100
L heparinase III (1U/mL,Heparinase III from Flavobac-
terium heparinum [E.C.4.2.2.8], an enzyme selective for
heparan sulfate within the glycocalyx, Fluka Chemie,
Buchs, Switzerland) was injected into the aortic lumen (n
6). Controls included 10 minutes incubation with hepari-
nase III-buffer only (n  4). Following incubation with
heparinase III or buffer, the aortas were either excised
immediately or reperfusion was induced. In further exper-
iments, 200 L DXS-Fluo was injected into the aortic
segment after heparinase treatment, followed by reperfu-
sion. All rats were kept under general anesthesia through-
out the experiments, including the reperfusion phase.
Immunostaining. Rat aortic rings were retrieved
(ischemic segment, nonischemic control segment), rinsed
carefully with saline, embedded in Tissue-Tek OCT com-
pound (Sakura Finetek Europe BV, Zoeterwoude, The
Netherlands), and stored at 	80°C until further analysis.
Five m sections were air-dried, acetone ﬁxed, hydrated
and labeled using a two-step indirect immunoﬂuorescence
Fig 1. Summary of the experimental design. DXS, dextran sul-
fate; DXS-Fluo, ﬂuorescein-labeled DXS; NaCl, saline controls;
Hep III, heparinase III; Hep III buffer, heparinase III buffer only;
n, number of animals per group.
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Fig 2. Immunoﬂuorescence staining for complement C1q, C4b/c, C3b/c, and C9 on rat aortic tissue. Essentially no
or minimal complement staining following ischemia-only (I-only). Complement activation and deposition after 90
minutes ischemia /120 minutes reperfusion following NaCl administration as well as after infusion of heparinase (Hep
III)/120 minutes reperfusion. Dextran sulfate (DXS) clearly reduces complement deposition. Scale bar represents
100m. All images are representative of at least 4 scored sections per experiment. Grading (average score  standard
deviation); where 0: no staining, 1: minimal focal or diffuse staining, 2: moderately strong focal or diffuse staining, 3:
extensive focal or diffuse staining.
Fig 3. Quantiﬁcation of ﬂuorescence intensity for complement staining/deposition of C1q, C4b/c, C3b/c, and C9.
Histograms show a representative image of staining intensity (ﬂuorescence, x-axis) from one of at least 4 individual
experiments. Shift of the curve towards the right indicates increased intensity and thus increased complement deposition.
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technique or immunohistochemical approach. The follow-
ing antibodies were used: rabbit antisera speciﬁc for human
C1q, C3b/c, and C4b/c (Dako, Glostrup, Denmark),
rabbit anti-rat C9 (kind gift of Prof. Paul Morgan, Cardiff,
UK), monoclonal mouse anti-human heparan sulfate
(Seikagaku, Tokyo, Japan), rabbit antiserum speciﬁc for
human von Willebrand Factor (vWF, Dako), and rabbit
anti-human tissue factor (TF; American Diagnostica Inc,
Stamford, Conn). Cross-reactivity with the respective rat
antigens was veriﬁed for all used antibodies and antisera.
Secondary antibodies used were goat anti-rabbit
IgG(HL)-FITC (Southern Biotechnology Associated,
Birmingham, Ala) sheep anti-rabbit (F(ab’)2)-Cy3
(Sigma), and rabbit anti-mouse (Ig)-FITC (Dako). Stain-
ing for phospho-JNK and phospho-ERK1/2 was per-
formed with polyclonal antibodies speciﬁc for phosphory-
lated JNK and ERK1/2 respectively (Cell Signaling;
BioConcept, Allschwil, Switzerland) followed by secondary
labeled polymer using the Envision HRP Kit and diamino-
benzidine chromogen kit (both Dako). After washing, the
slides were counterstained with hematoxylin. All slides were
mounted with SlowFade Light Antifade Kit (Molecular
Probes Europe, Leiden, The Netherlands).
Nuclear factor (NF) B was visualized using a rabbit
anti-NF B p65 (Abcam, Cambridge, Mass) antibody at
1:50 dilution, followed by secondary antibody (Dako) and
counterstaining with hematoxylin.
Images were acquired with a ﬂuorescence microscope
(Nikon Eclipse TE2000-U; Nikon Corporation, Tokyo,
Japan) and digital camera (Nikon DXM1200F). Images
were captured with identical exposure times and settings in
each experiment. For quantiﬁcation of ﬂuorescence inten-
sity, Image J software (http://rsb.info.nih.gov/ij/) was
used, in addition to grading of four samples per experiment
with respect to staining intensity (as a further control to
quantify staining): 0: essentially no staining; 1: minimal
focal or diffuse staining; 2: moderately strong focal or
diffuse staining; and 3: extensive diffuse staining. Sections
were prepared such that grading was performed in a
blinded manner by two independent observers.
For NF B staining six random ﬁelds were chosen and
nuclei staining positive for NF B were counted and di-
vided by the total number of nuclei identiﬁed in the ﬁeld.
Image J software was used for quantiﬁcation of staining.
TUNEL staining for apoptosis. Apoptosis within
the aortic wall was detected on serial 5 m thick cryosec-
tions in high-power ﬁelds by terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL)
according to themanufacturer’s instructions (In SituDeath
Cell Kit; Roche Diagnostics, Basel, Switzerland). As a
positive control, slides were incubated with DNAse1
(Sigma, Chemical Co, St Louis,Mo) to induceDNA strand
breaks. For every TUNEL stained section, a subsequent
section was stained with hematoxylin-eosin to visualize
total number of nuclei. Apoptosis was expressed by normal-
izing the results to the total number of nuclei per high-
power ﬁeld. Four high power ﬁelds per experiment and
section were analyzed.
Western blotting for MAP kinases. Aortic segments
were snap-frozen in liquid nitrogen and kept at 	80°C
until further processing for western blotting. Cell extracts
were prepared by lysing cells from the aortic tissue samples in
extraction buffer as described previously.18 Extracts of 40 g
were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and electrophoretically transferred to an
Immobilon-P membrane (Millipore, Billerica, Mass). Fol-
lowing blocking with 5% skim milk, the membrane was
incubated overnight at 4°Cwith the corresponding primary
Fig 4. Von Willebrand (vWF) and heparan sulfate proteoglycan
(HSPG) staining on rat aorta. Circumferential positive staining for
vWF in all experimental settings. Circumferential surface and wall
HSPG staining in ischemia-only (I-only) controls and DXS-treated
aorta. Diminished/abrogated HSPG staining in NaCl controls and
heparinase-treated aortas. Scale bar represents 100m. All images are
representative of at least 4 scored sections per experiment.Grading
(average score standarddeviation);where 0: no staining, 1:minimal
focal or diffuse staining, 2: moderately strong focal or diffuse staining,
3: extensive focal or diffuse staining.
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antibody (polyclonal antibodies raised in rabbits for detection
of JNK, ERK1/2, p38MAPK and their respective phosphor-
ylated counterparts; all Cell Signaling, BioConcept). This was
followed by washing and incubation with an appropriate
anti-rabbit alkaline phosphatase-conjugated secondary an-
tibody. Signal was detected by Western Blue (Promega,
Madison, Wis) stabilized substrate. Quantiﬁcation of the
signals was performed with NIH Image 1.62 software.
Statistics. Differences between as well as within the
experimental groups were analyzed by one-way-analysis of
variance (ANOVA). Post-hoc analysis was done using Bon-
ferroni adjustments. Differences were considered to be
signiﬁcant with a P value of less than .05. Data, unless
otherwise speciﬁed, are presented as average  standard
deviation in text and ﬁgures.
RESULTS
Tissue complement deposition. DXS treatment
markedly reduced complement deposition after IRI com-
pared with the NaCl control group: C1q (mean grading
Fig 5. A, Immunoﬂuorescence staining for tissue factor. Yellow arrowheads highlight surface tissue factor expression.
Marked increase in tissue factor expression in the NaCl group as compared to aortas from DXS-treated animals and
ischemia-only controls (I-only). Native (normal) aortas are used as a control. All images are representative of at least 4
scored sections per experiment. B, Image J software quantiﬁcation of ﬂuorescence intensity and grading of staining.
Left: the histogram shows a representative image of staining intensity (ﬂuorescence, x-axis) from one of at least 4
individual experiments. Shift of the curve towards the right indicates increased intensity and thus increased tissue factor
expression. Right: grading (average score  standard deviation); where 0: no staining, 1: minimal focal or diffuse
staining, 2: moderately strong focal or diffuse staining, 3: extensive focal or diffuse staining.
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score; 1.0 0.7 vs 2.3 0.7), C4b/c (0.8 0.7 vs 2.1
0.8), C3b/c (1.0 0.7 vs 2.3 0.7) and C9 (0.9 0.7 vs
2.1  0.8). This reduction was evident in stained tissue
sections (Fig 2), quantitatively represented as histograms
following analysis with image J software (Fig 3). Minimal
complement deposition on the endothelial surface was
detected after ischemia-only (mean grading score: C1q
0.4  0.5; C4c 0.4  0.5; C3c 0.8  0.7; C9 0.3  0.5).
A similar, though more extensive staining pattern of comple-
ment deposition was observed after 10 minutes heparinase
treatment followed by reperfusion compared with the NaCl
ischemia/reperfusion control group. No complement depo-
sition was detected upon heparinase administration without
reperfusion or heparinase buffer only (not shown).
Endothelial vWF and HSPG expression. Expres-
sion of vWF was essentially maintained and detected
circumferentially in all experimental settings. NaCl con-
trols showed reduced staining intensity and, in certain
experiments, focal absence of positivity, indicating par-
tial endothelial denudation (Fig 4). Intensity of HSPG
staining inversely correlated with complement deposi-
tion in all groups. Maximal HSPG staining (endothelial
and extracellular matrix/cellular membranes within the
vessel wall) was observed in native control aortas. HSPG
staining was slightly decreased after 90 minutes ischemia
only. A marked decrease or focal absence of HSPG was
noted following 120 minutes reperfusion in NaCl con-
trols. In contrast, HSPG intensity and distribution pat-
tern was maintained at ischemia-only levels following
DXS administration. Heparinase treatment almost en-
tirely abolished HSPG positivity, whereas heparinase
buffer had no effect (not shown).
Tissue factor expression. Compared with normal
controls, tissue factor expression markedly increased in the
NaCl group at the end of the 120-minute reperfusion phase
comparedwithaortas fromDXS-treatedanimals and ischemia-
only controls (Fig 5).
Binding of ﬂuorescein-labeled dextran sulfate
(DXS-Fluo). DXS-Fluo binding was only detected in aor-
tas subjected to ischemia or heparinase treatment and was
not found on native aorta or after heparinase buffer alone
(Fig 6, A). No DXS-Fluo binding was observed in other
inspected organs (lungs, liver, kidney, spleen; not shown).
TUNEL staining. Compared with normal controls
and aortas from ischemia-only experiments, noticeably
more TUNEL positive nuclei were observed in the NaCl
group within the aortic wall (Fig 6, B). DXS treatment
signiﬁcantly reduced TUNEL positivity within the aortic
Fig 6. A, Localized binding of ﬂuorescein-labeled DXS (DXS-Fluo) to ischemically damaged aorta as well as
heparinase-treated aorta. Yellow arrows show DXS binding. Additional binding deeper within the aortic wall
(particularly following heparinase treatment) is not marked with yellow arrows to retain clarity. No binding found to
non-ischemic aorta. Scale bar represents 50 m. B, Representative images of terminal deoxynucleotidyl transferase-
mediated dUTP nick end-labeling (TUNEL) staining on aorta from normal, DXS, and NaCl animals. Positive nuclei
stain brown (see black arrow and inlay), indicating apoptosis. Scale bar represents 50 m. Columns represent mean 
standard deviation of percent TUNEL positive nuclei per high power ﬁeld, P 0.032 for DXS vs. NaCl and P 0.047
for normal vs. NaCl.
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wall (TUNEL positive nuclei expressed as percentage of
total nuclei per high power ﬁeld: 8.5%  3.8% for DXS vs
21.4%  10.7% for NaCl, P  .032).
p38 MAPK: Western blot. p38 MAPK phosphoryla-
tion was signiﬁcantly increased in the NaCl controls (P 
.022, Fig 7, A) and heparinase III treated animals (P 
.007, not shown) compared with normal aorta. Neither
ischemia-only nor DXS treatment signiﬁcantly affected p38
activation (DXS: P  .110; ischemia only: P  .440 vs
normal).
ERK1/2: Western blot and staining. ERK1/2
phosphorylation was signiﬁcantly increased in all experi-
mental groups compared with normal aorta (P  .004 for
ischemia-only, P .0003 for NaCl controls, P .0001 for
DXS, Fig 7, B). ERK1/2 phosphorylation was not signiﬁ-
cantly higher in NaCl controls compared with ischemia-
only experiments (P .064). DXS treatment signiﬁcantly
reduced ERK1/2 activation compared with NaCl controls
(P  .005). Immunohistochemical staining for activated
ERK1/2, using an antibody speciﬁc for phosphorylated
ERK1/2, conﬁrmed increased levels in the NaCl controls
compared with the DXS treated animals.
JNK: Western blot and staining. JNK phosphoryla-
tion was signiﬁcantly increased in all experimental groups
compared with normal aorta (P 0.004 for ischemia-only,
P .0009 for NaCl controls, P .0003 for DXS, Fig 7,C).
DXS administration prior to reperfusion signiﬁcantly inhib-
ited JNK phosphorylation compared with NaCl controls
(P  .043), down to levels of ischemia-only. Immunohis-
tochemical staining for activated JNK, using an antibody
speciﬁc for phosphorylated JNK, conﬁrmed homogenously
increased levels in the NaCl controls compared with the
DXS treated animals.
NF B staining. Immunohistochemistry revealed that
the degree of IRI and complement activation correlated with
the extent of NF B nuclear translocation in the aortic wall.
Minimal nuclear NF Bwas observed in native aortas (Fig 8).
However, there was substantial nuclear NF B localization in
the control NaCl treated aortas, with evidently less transloca-
tion following DXS administration.
Fig 7. A, Western Blot results for MAPK activation. Ratio of phosphorylated (activated) p38MAPK to p38MAPK in
aortic tissue samples from normal, ischemia-only (I-only), NaCl controls and DXS-treated animals. Signiﬁcant increase
in theNaCl group as compared to normal aorta (P 0.02). DXS treatment and ischemia-only did not affect p38MAPK
activation (P 0.110, P 0.440 respectively). Ratio of phosphorylated (activated) c-Jun NH2-terminal kinase (JNK)
to JNK in aortic tissue samples (B). Signiﬁcant increase in all groups as compared to normal aorta (P  0.005). DXS
treatment signiﬁcantly reduced JNK activation versus NaCl controls (P  0.043). C, Ratio of phosphorylated
(activated) ERK1/2 to ERK1/2 in aortic tissue samples. Signiﬁcant increase in all groups as compared to normal aorta
(P  0.005). DXS treatment signiﬁcantly reduced ERK1/2 activation versus NaCl controls (P  0.005). All data are
mean  standard deviation. B and C, Representative images from immuno-histochemical staining for JNK and
ERK1/2 reveal reduced staining in native/normal and DXS aortas as compared to control NaCl aortas (brown color).
D, Image of representative Western Blot for native and phosphorylated p38 MAPK, ERK1/2 and JNK. Loading of 40
g per well, individual lanes represent one single experiment.
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DISCUSSION
Ischemia-induced damage, not only to the end organ
but also to the vasculature itself, is of importance, particu-
larly in vascular surgery that may necessitate temporary
vascular clamping. The ensuing reperfusion may lead to
substantial endothelial damage with HSPG release and
denudation, promoting activation of complement and co-
agulation and resulting in potentially extensive damage not
only to the end organ but also to the vasculature itself;
whether it is the microvasculature within the end organ or
the clamped (and at least partially ischemic) “conduit”
artery or segments thereof. Indeed, although the thickness
and composition of the endothelial glycocalyx differs ac-
cording to type and size of the vessel,19 the response of the
endothelium in particular and vasculature in general to
(ischemia/reperfusion) injury involves the release of
HSPG.5
In a recent study by Rehm et al, it was shown for the
ﬁrst time in humans that signiﬁcant shedding of the endo-
thelial glycocalyx occurs in patients undergoing major vas-
cular surgery with global and regional ischemia, including
surgery for infrarenal aortic aneurysm.20
Numerous aortic clampingmodels concentrate on end-
organ injury. Whilst the presented model inevitably also
affects the end organ, ie, hind limbs, with release of proin-
ﬂammatory mediators, it chieﬂy also allows for more de-
tailed immunohistochemical and biochemical studies of a
vessel more amenable to such investigation than the corre-
sponding microvasculature. By nature of the rather
straightforward anatomy and surgical technique, the herein
presented model essentially ensures quite standardized
complete bilateral hind limb ischemia. This will induce a
certain generalized inﬂammatory response in addition to
local aortic damage. However, this reﬂects the clinical
situation, where “target” tissue IRI provokes a proinﬂam-
matory and procoagulant reaction that will inevitably affect
the microvasculature within the ischemic tissue as well as
blood vessels, that, for instance in the case of vascular
surgical procedures, themselves may be subject to a certain
level of ischemic (or other) damage.
In ischemia/reperfusion injury (IRI), complement ac-
tivation and the effectiveness of its inhibition in providing
protection to various organs has been demonstrated in a
multitude of models.21 Here we show that the glycosami-
noglycan analog DXS attenuates IRI-induced aortic com-
plement activation and damage and reduces apoptosis
within the ischemic/reperfused segment. These results are
in line with our own work and previous studies from others,
where the use of glycosaminoglycan analogs such heparin,
reduced IRI through complement inhibition and endothe-
lial association.17,22
Whilst glycosaminoglycans, including heparin as well as
cell-surface HSPG, have been reported to modulateMAPK
signaling,23 complement itself inﬂuencesMAPK activation.
Sublytic amounts of C5b-9 activate the JNK and ERK
pathways, inducing mitogenic signaling in a B-cell line and
smoothmuscle cell proliferation in aortas.24 Also, constitutive
Fig 8. Representative images from immuno-histochemical staining
for nuclear factor (NF) kappa B reveal reduced nuclear staining in
native/normal and DXS aortas as compared to NaCl control aortas.
Nuclear positivity appears as a brown staining (see arrow heads in
inlay). Scale bar represents 50m.Quantiﬁcation of staining intensity
using Image J software. The graph represents the total area of posi-
tivity (brown nuclei) for NF kappa B staining on aortic samples. Bars
represent mean standard deviation.
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ERK activation may exacerbate complement-mediated injury
to glomerular epithelial cells.25 Inhibition of MAPK activa-
tion, for instance the stress-activated JNKs and p38-MAPKs,
has been shown to reduce (complement-mediated) injury in
various target organs and models.26 To date, however, it
remains unknown, whether complement inhibition and
accompanying modulation of MAPK signaling may be
beneﬁcial in reducing IRI-induced tissue injury. Our results
indicate that complement inhibition by DXS is associated
with reduced JNK and ERK1/2 activation. The latter effect
by itself may provide one way by which DXS modulates the
proinﬂammatory events associated with ischemia and reper-
fusion. The reduction in MAPK activation is accompanied
by reduced tissue factor expression in the DXS treated
aortas and correlated with reduced NF B nuclear translo-
cation, as we have already previously reported in an in vitro
setting.14Whether DXS also signiﬁcantly affects the expres-
sion of intercellular adhesion molecules remains to be in-
vestigated. Inﬂuencing signaling pathways through modu-
lation of protein kinases may prove an effective strategy to
tackle a variety of diseases. However, there remains a degree
of uncertainty as to whether inhibition or indeed activation
of MAPK, proves beneﬁcial or detrimental.27 In particular,
effects may also be species- and model-dependent.28
Binding of DXS to the damaged endothelium and
aortic wall, visualized using ﬂuorescein-labeled DXS, was
observed following local administration. Binding was local-
ized to ischemically damaged tissue and was not detected in
non-ischemic aorta or other organs. DXS was also detected
on the endothelium and within the aortic wall following
pretreatment of the aorta with heparinase III, which, like
other enzymes29 removes HSPG from the endothelial sur-
face. This ﬁnding correlates with previous work, demon-
strating increased binding of DXS to porcine endothelial
cells following heparinase treatment.13
The pharmacologically-induced HSPG release mim-
icked the HSPG loss detectable after 90 minutes ischemia,
which was ampliﬁed following subsequent reperfusion. DXS
largely prevented reperfusion-induced HSPG shedding.
However, the increased staining intensity after DXS adminis-
tration (Fig 3) may at least partly be due to cross-reaction of
the anti-heparan sulfate antibody with endothelial-bound
DXS. Cross-reactivity of this antibody with DXS was re-
cently conﬁrmed in a competitive inhibition experiment.30
Heparan sulfate, like medicinal heparin, enhances the activ-
ity of antithrombin, thereby contributing to the inactiva-
tion of thrombin and activated FXa, respectively.31 Hepa-
rinase treatment of endothelial cells reduces antithrombin
binding, suggesting that this interaction is indeedmediated
by heparan sulfate.32 Replacing the shed HSPG layer by a
glycosaminoglycan analog, such as DXS, or indeed, pre-
venting reperfusion-induced shedding, may help restore
this essential property of “surface regulation” of the coag-
ulation system.
In conclusion, we provide evidence that low molecular
weight DXS substantially reduces endothelial damage fol-
lowing ischemia and reperfusion in an infrarenal aortic
clamping model in rats. DXS provides cytoprotection
through association with denudated endothelium and local
complement inhibition, and modulates signaling through
MAPK pathways in this setting. Local cytoprotection of
damaged endothelium using substances such as DXS,
which functionally restore the anti-inﬂammatory and anti-
coagulant properties of the luminal glycocalyx, may provide
a novel way to attenuate endothelial reperfusion-induced
injury in the clinical setting.
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